BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $507,000 | +38.1% | 19,259 | -9.6% | 0.00% | – |
| Q2 2023 | $367,000 | -18.8% | 21,301 | -21.8% | 0.00% | – |
| Q1 2023 | $452,000 | +195.4% | 27,254 | +34.6% | 0.00% | – |
| Q4 2022 | $153,000 | +8.5% | 20,244 | +43.1% | 0.00% | – |
| Q3 2022 | $141,000 | -25.4% | 14,146 | -32.0% | 0.00% | – |
| Q2 2022 | $189,000 | -10.0% | 20,806 | +0.5% | 0.00% | – |
| Q1 2022 | $210,000 | -62.0% | 20,706 | -37.6% | 0.00% | – |
| Q4 2021 | $553,000 | +36.5% | 33,168 | +283.7% | 0.00% | – |
| Q3 2021 | $405,000 | -27.3% | 8,645 | -5.4% | 0.00% | – |
| Q2 2021 | $557,000 | -2.3% | 9,141 | -1.3% | 0.00% | – |
| Q1 2021 | $570,000 | +540.4% | 9,258 | +635.3% | 0.00% | – |
| Q4 2020 | $89,000 | +4350.0% | 1,259 | +1724.6% | 0.00% | – |
| Q2 2020 | $2,000 | -80.0% | 69 | -80.3% | 0.00% | – |
| Q1 2020 | $10,000 | -76.7% | 351 | -71.6% | 0.00% | – |
| Q4 2019 | $43,000 | +1333.3% | 1,238 | +703.9% | 0.00% | – |
| Q3 2019 | $3,000 | – | 154 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |